Functional Effects of KCNQ K(+) Channels in Airway Smooth Muscle by Evseev, Alexey I. et al.
Old Dominion University
ODU Digital Commons
Bioelectrics Publications Frank Reidy Research Center for Bioelectrics
2013
Functional Effects of KCNQ K(+) Channels in
Airway Smooth Muscle
Alexey I. Evseev
Iurii Semenov
Old Dominion University, isemenov@odu.edu
Crystal R. Archer
Jorge L. Medina
Peter H. Dube
See next page for additional authors
Follow this and additional works at: https://digitalcommons.odu.edu/bioelectrics_pubs
Part of the Physiology Commons
This Article is brought to you for free and open access by the Frank Reidy Research Center for Bioelectrics at ODU Digital Commons. It has been
accepted for inclusion in Bioelectrics Publications by an authorized administrator of ODU Digital Commons. For more information, please contact
digitalcommons@odu.edu.
Repository Citation
Evseev, Alexey I.; Semenov, Iurii; Archer, Crystal R.; Medina, Jorge L.; Dube, Peter H.; Shapiro, Mark S.; and Brenner, Robert,
"Functional Effects of KCNQ K(+) Channels in Airway Smooth Muscle" (2013). Bioelectrics Publications. 51.
https://digitalcommons.odu.edu/bioelectrics_pubs/51
Original Publication Citation
Evseev, A.I., Semenov, I., Archer, C.R., Medina, J.L., Dube, P.H., Shapiro, M.S., & Brenner, R. (2013). Functional effects of KCNQ
K(+) channels in airway smooth muscle. Frontiers in Physiology, 4(Article #277), 1-11. doi: 10.3389/fphys.2013.00277
Authors
Alexey I. Evseev, Iurii Semenov, Crystal R. Archer, Jorge L. Medina, Peter H. Dube, Mark S. Shapiro, and
Robert Brenner
This article is available at ODU Digital Commons: https://digitalcommons.odu.edu/bioelectrics_pubs/51
ORIGINAL RESEARCH ARTICLE
published: 07 October 2013
doi: 10.3389/fphys.2013.00277
Functional effects of KCNQ K+ channels in airway
smooth muscle
Alexey I. Evseev1, Iurii Semenov1, Crystal R. Archer1, Jorge L. Medina2, Peter H. Dube2,
Mark S. Shapiro1* and Robert Brenner1*
1 Department of Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
2 Department of Microbiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
Edited by:
Brendan J. Canning, Johns Hopkins
School of Medicine, USA
Reviewed by:
Jana Plevkova, Jessenius Faculty of
Medicine in Martin, Slovakia
Brad Undem, Johns Hopkins School
of Medicine, USA
*Correspondence:
Mark S. Shapiro and Robert Brenner,
Department of Physiology,
University of Texas Health Science
Center at San Antonio, 7703 Floyd
Curl Drive, San Antonio, TX 78229,
USA
e-mail: shapirom@uthscsa.edu;
brennerr@uthscsa.edu
KCNQ (Kv7) channels underlie a voltage-gated K+ current best known for control of
neuronal excitability, and its inhibition by Gq/11-coupled, muscarinic signaling. Studies
have indicated expression of KCNQ channels in airway smooth muscle (ASM), a
tissue that is predominantly regulated by muscarinic receptor signaling. Therefore, we
investigated the function of KCNQ channels in rodent ASM and their interplay with
Gq/11-coupled M3 muscarinic receptors. Perforated-patch clamp of dissociated ASM cells
detected a K+ current inhibited by the KCNQ antagonist, XE991, and augmented by the
specific agonist, flupirtine. KCNQ channels begin to activate at voltages near resting
potentials for ASM cells, and indeed XE991 depolarized resting membrane potentials.
Muscarinic receptor activation inhibited KCNQ current weakly (∼20%) at concentrations
half-maximal for contractions. Thus, we were surprised to see that KCNQ had no affect
on membrane voltage or muscle contractility following muscarinic activation. Further,
M3 receptor-specific antagonist J104129 fumarate alone did not reveal KCNQ effects
on muscarinic evoked depolarization or contractility. However, a role for KCNQ channels
was revealed when BK-K+ channel activities are reduced. While KCNQ channels do
control resting potentials, they appear to play a redundant role with BK calcium-activated
K+ channels during ASM muscarinic signaling. In contrast to effect of antagonist, we
observe that KCNQ agonist flupirtine caused a significant hyperpolarization and reduced
contraction in vitro irrespective of muscarinic activation. Using non-invasive whole animal
plethysmography, the clinically approved KCNQ agonist retigabine caused a transient
reduction in indexes of airway resistance in both wild type and BK β1 knockout (KO) mice
treated with the muscarinic agonist. These findings indicate that KCNQ channels can be
recruited via agonists to oppose muscarinic evoked contractions and may be of therapeutic
value as bronchodilators.
Keywords: KCNQ, Kv7, airway smoothmuscle, muscarinic receptors, patch-clamp electrophysiology, voltage-gated
potassium channels
INTRODUCTION
The control of membrane voltage by K+ channels serves as a
negative feedback to oppose voltage-dependent calcium influx
pathways that contribute to airway smooth muscle (ASM) con-
traction. K+ channel agonists may be useful as bronchodilators
for asthma since ASM hyperpolarization by K+ channel openers
can partly relax ASM (Pelaia et al., 2002). In addition, the most
common treatments for asthma, β-adrenergic agonists, appar-
ently confer much of their effects through activation of large
conductance Ca2+-activated (BK-type) K+ channels (Kotlikoff
and Kamm, 1996).
Recent studies have uncovered a new role for KCNQ (Kv7) K+
channels in control of contraction of various smooth muscle cell
types (Greenwood and Ohya, 2009; Gurney et al., 2010), includ-
ing guinea pig and human ASM (Brueggemann et al., 2012).
Called “M channels” for their depression by stimulation of mus-
carinic acetylcholine receptors (mAChRs) in neurons, they have
an established role in regulation of excitability in nerve and heart
(Brown et al., 1997). KCNQ channels are encoded by five genes
(KCNQ1–5) and may associate with KCNE accessory β-subunits
in a tissue-specific fashion (Soldovieri et al., 2011). Neuronal
KCNQ channels are multifariously composed of KCNQ2–5 sub-
units (Wang et al., 1998; Schroeder et al., 2000; Shah et al., 2002).
Recent studies suggest that KCNQ1,4, and 5 are the predomi-
nant subunits in smooth muscle (Greenwood and Ohya, 2009).
In sympathetic ganglia, KCNQ channels are inhibited by mAChR
agonists via depletion of phosphatidylinositol 4,5-bisphosphate
(PIP2) following cleavage by phospholipase C (PLC); in addition,
stimulation of a number of other PLC-coupled receptors also
modulate KCNQ channels via multiple intracellular mechanisms
(Hernandez et al., 2008). Robust expression of KCNQ chan-
nels composed of KCNQ1,4,5 subunits has been documented
in vascular smooth muscle, in which they, like BK channels,
play a prominent role in controlling contraction Mackie and
Byron, 2008; Greenwood and Ohya, 2009). In addition to vas-
cular smooth muscle, KCNQ channels moderate constriction of
bladder, myometrium, and gut smooth muscle (Anderson et al.,
2009; Greenwood et al., 2009; Jepps et al., 2009; Joshi et al.,
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2009), implicating KCNQ channels as novel targets for numer-
ous disease states involving smooth muscle (Mackie and Byron,
2008). Expression of KCNQ3 and 5 channels has been suggested
in airway epithelia (Greenwood et al., 2009) and ASM (Kakad
et al., 2011), suggesting the nascent emergence of an, as yet,
under-studied field with high relevance to pulmonary health and
disease.
Given the critical role of PLC-coupled M3 mAChRs in ASM,
it seems logical that acetylcholine (ACh) acts in those cells, at
least in part, by modulation of KCNQ channel activity, how-
ever, this hypothesis remains to be tested. Moreover, a number
of KCNQ openers have been developed that were first targeted as
anti-epileptics (Padilla et al., 2009; Wickenden andMcNaughton-
Smith, 2009; Fritch et al., 2010). Thus, there is the exciting
possibility that novel drugs targeting KCNQ channels may pro-
vide novel therapeutics for smooth muscle disorders, including
asthma.
Here, we address the role of KCNQ channels in control of
membrane voltage and contractions of ASM. Whereas KCNQ
channels have been shown to moderate muscarinic agonist-
evoked contractions of ASM (Brueggemann et al., 2012), their
role in the context of muscarinic signaling and their relationship
to other K+ currents needs further study in that tissue. For exam-
ple, it is unclear whether M-current inhibition of KCNQ channels
is relevant to ASM and how this might affect KCNQ agonists as
bronchodilators. Do KCNQ channels have redundant function
with the more established ASM K+ channel, the BK channel, or
do the two types of K+ channels work in parallel? In this study, we
investigate the role of KCNQ channels in mouse and rat tracheal
smooth muscle (TSM). We use KCNQ channel pharmacology to
evaluate the functional consequences of KCNQ currents on volt-
age and contraction of rodent ASM. We also utilize BK channel
β1 knockout (KO) mice to understand the complementary role of
BK and KCNQ channels in ASM.
MATERIALS AND METHODS
ETHICAL APPROVAL
All animal procedures were designed to be as humane as possible,
and were reviewed and approved by the University of Texas Health
Science Center at San Antonio Institutional Animal Care and Use
Committee. These procedures were in accordance with the U.S.
National Institutes of Health guidelines.
TISSUE PREPARATIONS AND CONTRACTION RECORDINGS
The BK channel β1 subunit KO mice are congenic by seven gen-
erations of inbreeding to the C57BL/6 line of Jackson Labs (strain
C57BL/6J) and maintained as homozygous lines. Control animals
used in these studies were 2–3 month old C57BL/6J mice strain
from Jackson Labs, or 2–3 week old rats (Sprague Dawley) from
Charles River Labs. For tracheal constriction studies we used pre-
viously published protocols (Semenov et al., 2012). Animals were
deeply anesthetized with isoflurane and then sacrificed by cervi-
cal dislocation. Trachea were quickly removed and dissected clean
of surrounding tissues in ice-cold normal physiological saline
solution (PSS). The tracheal tube was cut below the pharynx
and above the primary bronchus bifurcation. Two metal wires,
attached to a force transducer and micrometer (Radnoti, LLC),
were threaded into the lumen of the trachea. The trachea was
placed into an organ bath oxygenated by an O2-CO2 mixture
(95% O2, 5% CO2), at 37◦C. Resting tension was continuously
readjusted to 10 mN for 1 h and then challenged with 67mM K+
PSS twice or more until reproducible contraction responses were
achieved. Subsequent experimental challenges with drugs were
normalized to the constriction response to the 67mM K+ PSS
solution. In 67mM K+ PSS, the K+ reversal potential is depo-
larized and therefore K+ currents are unlikely to play a role in
controlling membrane potential and contraction tone. For exper-
iments that involve two muscarinic challenges, we found that
the second challenge does not show significant fatigue (P = 0.19,
N = 9 for WT, P = 0.18, N = 9 for KO, students paired t-test).
On average, the second challenge shows less than 1% reduction in
response from that of first challenge for WT and β1 KO trachea,
respectively. Normal PSS used was (mM) 119 NaCl, 4.7 KCl, 2.0
CaCl2, 1.0 KH2PO4, 1.17 MgSO4, 18 NaHCO3, 0.026 EDTA, 11
glucose, and 12.5 sucrose. The pH of the solution was adjusted to
7.35 by a 95% O2 - 5% CO2 mixture. The 67mM K+ PSS utilized
reduced sodium (56.7mM NaCl) to maintain proper osmolar-
ity. “Low K+” PSS solution was used to measure contractions
in relatively hyperpolarized conditions. Low K+ PSS consisted of
1.0mM K+ derived from the KH2PO4 in the PSS solution, with
no added KCl. Normal PSS has a total 5.7mM K+ derived from
4.7mM KCl plus 1.0mM KH2PO4. All other ingredients were
unchanged.
TRACHEAL SMOOTH MUSCLE CELL ISOLATION AND PATCH CLAMP
RECORDING
Tracheas were isolated as described above. The dorsal muscle
layer was cut away from the hyaline cartilage rings and minced
into ∼1-mm pieces in Ca2+-free HEPES-buffered Krebs solu-
tion (140mMNaCl, 4.7mMKCl, 1.13mMMgCl, 10mMHEPES,
10mM glucose, pH 7.3). After addition of 2.5U/ml papain
(Worthington), 1mg/ml BSA fraction V, and 1mg/ml dithio-
threitol, TSM tissue was agitated at 37◦C on a shaking platform
(250moves/min) for 20min. Tissue was washed once with the
Ca2+-free Krebs solution and digested with 12.5U/ml of type
VII collagenase (Sigma Chemical) for 10min on a rocking plat-
form at 37◦C. Digested pieces of tissue were washed three times
in Ca2+-free Krebs-BSA solution by centrifugation (750 g for
2min). The tissue was then triturated up to 5min to disburse
single tracheal myocytes. TSM cells were stored on ice in Ca2+-
free Krebs-BSA solution and used the same day. A small (50μl)
aliquot of the solution containing isolated tracheal myocytes was
placed in an open 1.0ml perfusion chambermounted on the stage
of an inverted microscope. The TSM cells were allowed to adhere
to the glass bottom of the chamber for 20min and then were
perfused (2ml/min) with Krebs solution.
Membrane potentials (Vm) and ionic currents of TSM
cells were measured using perforated-patch whole cell record-
ings. Pipettes were pulled from borosilicate glass capillaries
(1B150F-4; World Precision Instruments, Sarasota, FL) using a
Flaming/Brown micropipette puller P-97 (Sutter Instruments,
Novato, CA) and had resistances of 2–4M when filled with
internal solution and measured in standard bath solution.
Membrane current was measured with pipette and membrane
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capacitance cancellation, sampled at 100μs, and filtered at
2.9 kHz using an EPC-10 amplifier, and PATCHMASTER soft-
ware (HEKA/InstruTech, Port Washington, NY). In all experi-
ments, the perforated-patch method of recording was used with
amphotericin B (600 ng/ml) in the pipette (Rae et al., 1991).
Amphotericin was prepared as a stock solution as 60mg/ml in
DMSO. The access resistance was typically 10–20M 5–10min
after seal formation. Cells were placed in 800μl perfusion cham-
ber through which solution flowed at 1.5–2ml/min. Inflow to
the chamber was by gravity from several reservoirs, selectable
by activation of solenoid valves (Warner Instruments, Hamden,
CT). Bath solution exchange was essentially complete by <30 s.
Experiments were performed at room temperature.
UNRESTRAINED WHOLE ANIMAL PLETHYSMOGRAPHY
Unrestrained whole animal plethysmography of mice was con-
ducted using the BUXCO system (Buxco Research Systems,
Wilmington, NC, USA) according to previous procedures
(Lomask, 2006). Eight to twelve week old animals were allowed
20min to acclimate in the chambers. The challenge was delivered
in a final volume of 0.5ml that was nebulized into 8 chambers
for approximately the first 2min of challenge. Airway resistance,
inferred from the parameter PenH (Lomask, 2006), was measured
before and after introduction of nebulized methacholine (McH,
50mg/ml) into the plethysmography chambers. After an initial
challenge of McH (McH1), followed by a 20min rest, a second
McH challenge (McH2) was given, either alone or together with
nebulized retigabine (RTG, 200μM) and Penh was measured for
10min. The Penh baseline values were subtracted from the data.
DATA ANALYSIS
Igor 5 (Igor, WaveMetrics Inc.), KaleidaGraph 4.1.1 (Synergy
Software), and Excel 2007 (Microsoft Corp.) were used for sta-
tistical analyses. Significance was determined with paired or
unpaired t-test. In the cases when more than two experimen-
tal groups were compared, a One-Way ANOVA was applied
to determine variability among groups. A post-hoc Tukey HSD
test was used to compare individual groups. For comparison of
two groups with multiple factors, we used a Two-Way ANOVA
to distinguish if the groups were different. The effects were
deemed significant when a P < 0.05 was obtained. The results
are expressed as the means ± standard error of means where
applicable.
KCNQ EXPRESSION STUDIES
RT-PCR
Tracheal muscle was dissected and pooled from either five wild
type or five β1 KO mice. Rat tracheas were analyzed from
four individual animals and expression values reflect mean data.
The muscle RNA was extracted using Ambion Purelink RNA
kit. One microgram of RNA was used for random primer,
reverse transcriptase reactions using Applied Biosystems Reverse
Transcriptase kit. 1/10 of the cDNA synthesis was used for SYBR
green-based PCR amplification of cDNA using the forward and
reverse primers listed in Table 1. The thermocycle reactions were
conducted in triplicate. Amplification condition was 95◦C for
10min for PCR polymerase activation, and 2 cycle steps of 95◦C
for 15 s, and 60◦C for 60 s for 40 cycles. The specificity of the
amplification product was confirmed using melting curve anal-
ysis and DNA gel electrophoresis (Figure 1A). The sample cycle
thresholds (Ct) were calculated automatically using the Applied
Biosystems software to minimize user bias. The mRNA concen-
trations were calculated using Ct levels of target genes normalized
to that of β-actin.
IMMUNOSTAINING
Whole lungs were removed from adult rats. To quickly fix air-
way passages and associated smooth muscle, an 18 gauge needle
was inserted into the trachea and a 4% paraformaldehyde/PBS
solution was injected and withdrawn several times (effectively
replacing air with fixative). The whole lungs were then fixed
overnight in 4% paraformaldehyde/PBS, and washed in 20%
sucrose/PBS for a second day. Frozen sections were cut in a slid-
ing microtome at 25 micron thickness and immunostained using
the free-floating section technique. Primary antibodies used were
Neuromab monoclonal antibodies against KCNQ1 (N37/A10,
0.6μg/ml), KCNQ2 (N26A/23, 0.6μg/ml), and KCNQ4 (N43/6,
0.6μg/ml) and a non-commercial antibody against KCNQ3
(Guinea Pig Anti-N terminal KCNQ3, a gift from Ed Cooper,
Baylor College of Medicine) that has been used successfully in
Table 1 | Mouse (mKCNQ) and rat (rKCNQ) primers utilized for quantitative RT-PCR.
Gene Forward primer Reverse primer Product (nt)
mKCNQ1 GAGGGCAGCACGGTCTATG GTGGTACACGAAACACTTCCAA 243
rKCNQ1 ACAGGGTGGAAGACAAGGTG TGGCTACGACTTGTGACCTG 126
mKCNQ2 CAGTACCGAGTTCTTGAGGCT CTCTGCAATGTAGGGCCTGA 226
rKCNQ2 GTGACTGCGTGGTACATTGG TGGTTGTCAGGGTGATCAGA 136
mKCNQ3 GAGCCGACAAAGACGGGAC CTGTACTTGGCGTTGTTCCTC 136
rKCNQ3 GCCCGTTGGCTTAAACAATA TCTTCTGTCATGGGGTCTCC 111
mKCNQ4 TTGAGCAGTATTCAGCAGGACA GGACCCTTATCGCCCTTCTC 127
rKCNQ4 GTGGTCTACGCGCACAGTAA GAGTTGGCATCCTTCTCAGC 107
mKCNQ5 GTCGGCGCAACGTCAAGTA AACCAAACACAAGGAGAAAAACG 110
rKCNQ5 AATATTTTCGCCACGTCAGC CTTGCTGTGAGCGTAAACCA 123
mb-actin AGGTCATCACTATTGGCAACGA CACTTCATGATGGAATTGAATGTAG 117
rb-actin AGCCATGTACGTAGCCATCC ACCCTCATAGATGGGCACAG 115
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FIGURE 1 | Expression of KCNQ genes in mouse and rat trachea. (A)
RT-PCR of mouse KCNQ cDNA yields a single expected product size for
each KCNQ channel gene. Shown are PCR products following 30 cycles
of amplification. The expected amplification products are 243 (mKCNQ1),
226 (mKCNQ2), 136 (mKCNQ3), 127 (mKCNQ4), and 110 (mKCNQ5). The
DNA ladder is a 50 bp increment ladder (New England Biolabs N3236).
(B) Quantitative, real-time RT-PCR from pooled mouse trachea muscle
RNA (panel B1) and rat trachea muscle RNA (n = 4, panel B2) of KCNQ
subunit expression normalized to β-actin expression. Gray bars in panel
(B1) are from BK β1 knockout tissues. (C) Immunostaining against
KCNQ1–4, and BK β1 (KCNMB1) proteins in rat lung sections. Color
panels on the left of (CA,CB) are pseudocolor images from double
immunofluorescence staining against KCNQ (middle panels) and KCNMB1
(BK β1) (right panels). Panels (CC,CD) include a light image of tissues in
the left panels, and immunostaining in right panels. Photographs are
taken with the interstitial space to the left, and lumen of the airway to
the right. Smooth muscle (SM) and epithelial cell (Ep) layers are
indicated. Scale bars are 25 microns.
the past (Klinger et al., 2011). These antibodies give only specific
signals on transiently transfected COS cells as assayed by west-
ern blots and/or immunostaining (http://neuromab.ucdavis.edu/
catalog.cfm). Guinea pig anti-KCNQ3 (1:1000) antibodies have
been successfully utilized for staining of brain sections (Klinger
et al., 2011). We did not find antibodies that gave a specific signal
for KCNQ5 protein, and therefore immunostaining for KCNQ5
was not performed. Anti-BK channel KCNMB1 (β1 subunit)
was using an affinity-purified rabbit polyclonal (1:2000, Pierce
Antibody, A1-924). Antibody concentrations used were those
with highest dilution that gave a specific signal as compared to
no primary antibody controls. Immunostaining and washes were
accomplished with 0.2% Tween-20, PBS, and 10% goat serum
as blocking agent. Secondary antibodies were at 1:2000 dilution.
Images were obtained using an epifluorescent microscope using
a 20X 0.5 NA fluor objective and 5 s exposure for all sections
including negative controls.
RESULTS
AIRWAY SMOOTH MUSCLE PREDOMINATELY EXPRESS KCNQ1, 4, AND
5 SUBUNITS
Previously, KCNQ channels were studied in guinea pig ASM
and human lung slices (Brueggemann et al., 2012). We first
determined if rodents (rats and mice) could also be used as
models for KCNQ channel function in ASM, and wished to
understand effects of KCNQ channels on resting potentials and
muscarinic-evoked contractions in vitro and in vivo. We assayed
KCNQ mRNA expression using quantitative PCR from dissected
tracheal muscle. Figure 1A shows that subunit-specific primers
specifically detected individual KCNQ subtypes. Real-time, quan-
titative PCR indicate relative expression levels of KCNQ mRNAs
from pooled mouse tissues appear very similar to that previ-
ously observed in human airway (Brueggemann et al., 2012) in
which KCNQ1 is the predominant subtype followed by KCNQ4
and weak expression of KCNQ5 (expression relative to β-actin:
KCNQ1, 366e−6, KCNQ4, 243e−6, KCNQ5, 32e−6, Figure 1B1,
black bars). Like mice, rat trachea (n = 4) show greatest expres-
sion of KCNQ1. However, KCNQ5 is somewhat greater than
KCNQ4 expression (Figure 1B2). In rat, we also observed low
levels of KCNQ3 expression that is relatively absent in mice
(Figure 1B2). We also assayed KCNQ changes in BK channel
β1 KO mice, which were used in experiments described later
in this study (Figures 5–6). BK channel β1 gene KO mice dis-
played similar expression levels of KCNQ1–5 as wild type mice
(Figure 1B1, gray plots) indicating that BK channel β1 KO mice
do not compensate with changes in KCNQ channel expression.
Immunostaining of rat lung sections was used to corroborate
expression of KCNQ channels in ASM cells. Lung sections of
lower airway were immunostained with KCNQ subunit-specific
antibodies (see Methods). We observed relatively strong stain-
ing of KCNQ1 and KCNQ4 proteins in the smooth muscle layer
lining the airway (Fluorescein signal, Figures 1CA,CB, middle
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panels) that was absent with no-primary antibody controls
(not shown) or with KCNQ2 and KCNQ3 primary antibodies
(Figures 1CC,CD). This appeared to overlap with BK KCNMB1
(β1) protein expression that is documented to express in ASM
(Brenner et al., 2000; Semenov et al., 2006) (Texas Red signal,
Figures 1CA,CB, right panels). Indeed, the Fluorescein KCNQ
(green) and Texas Red BK β1 (red) signals show a predomi-
nant overlap (yellow) in the smooth muscle layer of the airway
(Figures 1CA,CB, left panels). Consistent with RT-PCR, KCNQ2
was not detected in lung (Figure 1CC), and KCNQ3 immunos-
taining showed weak expression, albeit in epithelial cell lay-
ers of the airway (Figure 1CD). Unfortunately, we could not
obtain an antibody that specifically detects KCNQ5 protein in
airway.
THE KCNQ CURRENT IN ASM CELLS IS SENSITIVE TO KCNQ-SPECIFIC
DRUGS AND MODESTLY DEPRESSED BY MUSCARINIC AGONISTS
KCNQ currents were assayed in acutely dissociated tracheal mus-
cle cells using perforated, whole-cell patch clamp recordings. The
bath solution included the BK channel blocker paxilline (1μM)
to enrich for the KCNQ current fraction. To estimate KCNQ
currents in these experiments, we used two approaches. The
first exploits the much slower kinetics of KCNQ current acti-
vation, compared to other Kv channels. The second approach
was pharmacological, using KCNQ channel openers and block-
ers. Thus, we used long (2 s) voltage commands and quantified
the KCNQ current as that present during the last 400ms of
each sweep (Figure 2A, control panel), a paradigm similar to
that used previously in the study of KCNQ channels in ASM
(Brueggemann et al., 2012). Indeed, currents in response to
voltages positive to −50mV displayed an early inactivating com-
ponent, and a sustained component that is dominated by current
from KCNQ channels (Figure 2A). This conclusion was strength-
ened using paired recordings in the presence or absence of the
KCNQ opener, flupirtine and blocker, XE991 (Zaczek et al.,
1998). At potentials positive to −60mV, flupertine (10μM)
increased the late component of the currents, whereas XE991
(10μM) nearly abolished it. Representative currents from rat
ASM cells are shown in Figure 2A, pooled current-voltage data
in Figure 2B, and pooled activation curves in Figure 2C. The
current-voltage relations indicate that the late component is
eliminated by XE991 (Figure 2B), consistent with KCNQ chan-
nels underlying the majority of the sustained voltage-dependent
K+ current (with BK channels blocked). Consistent with pre-
vious work, flupirtine roughly doubled the KCNQ current at
potentials positive to −40mV (Figures 2B,D), and shifted the
conductance/voltage relation to more hyperpolarized potentials
(Figure 2C) (Wickenden et al., 2000). We approximated the
voltage-dependence of KCNQ current activation by fitting the
G/Gmax vs. voltage relations to Boltzmann functions, in which
the maximum and minimum were constrained to unity and zero,
respectively. In control, the V1/2 and slope factor were −28 ±
1.2mV and 9.9 ± 0.3mV (n = 26), and with flupirtine, they were
−36 ± 1.4mV and 9.1 ± 0.3mV (n = 26), respectively, consis-
tent with the biophysical and pharmacological behavior of KCNQ
channels. Since the qRT-PCR data indicated subtle differences
FIGURE 2 | Isolation of KCNQ currents from tracheal smooth muscle
cells. (A) Representative whole-cell currents from acutely dissociated
tracheal smooth muscle cells. All recordings were made with 1μM paxilline
in the bath to block BK K+ currents. The KCNQ component was quantified
from the final 500ms of a 2 s voltage command (for panels B–F). Bottom
panels show the subtracted currents as indicated. (B) Average sustained
current-voltage relationship. (C) Conductance-voltage relationship. (D)
Average sustained current amplitudes measured at −20mV holding potential.
(E) Representative sustained current amplitudes (at −20mV) with sequential
application of 0.5 and 10μM carbachol, and 10μM KCNQ antagonist XE991.
(F) Average % remaining current from experiments as in panel (E). ∗p < 0.05;
∗∗∗p < 0.0001, evaluated by unpaired, two-tailed t-test.
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in the expression profile of KCNQ1–5 subunits across species,
we also investigated KCNQ currents in mouse ASM, and saw a
similar effect of flupirtine and XE991 on the currents attributed
to KCNQ channels (Figure 2D). In rat ASM cells, the persis-
tent current at −20mV was 9.2 ± 1.8 pA (n = 26), which was
increased to 16.8 ± 2.7 pA (n = 26) by flupirtine, but reduced
to 0.5 ± 0.2 pA (n = 23) by XE991. In mouse ASM cells, the
values were 6.4 ± 2.0 pA (n = 7), 13.2 ± 3.2 (n = 5) and 1.2 ±
0.6 pA (n = 4), respectively. Similarly, flupirtine shifted the V1/2
from −26 ± 2mV, slope factor 9 ± 0.5 (n = 7) to −36 ± 1.7mV,
slope factor 8.9 ± 0.6 (n = 7). Thus, both rat and mouse ASM
cells display KCNQ current of similar current amplitudes and
pharmacological sensitivities.
In neurons, KCNQ2/3 channels are strongly inhibited by Gq-
coupled receptors that activate PLC, inducing hydrolysis of PIP2
(Hernandez et al., 2008). In ASM, partial inhibition of KCNQ
currents (∼50% in guinea pig) by ASM constrictors such as his-
tamine andmuscarinic agonists has been reported (Brueggemann
et al., 2012). Since ACh, acting onmuscarinic acetylcholine recep-
tors (mACh), is the predominant stimulus for contraction of
ASM, it is of interest to know if the role of KCNQ channels in
control of airway tone is dependent on the extent of mAChR
stimulation. We used carbachol (CCh), the classically-used mus-
carinic agonist in such airway studies, as an agonist. Under similar
perforated-patch clamp conditions as above, we tested the inhi-
bition produced by CCh at 0.5μM and 10μM, corresponding to
concentrations that produce half-maximal, or nearmaximal, con-
traction of trachea, respectively. We observed a relatively small
inhibition of KCNQ current at 0.5μM CCh, and one substan-
tially larger at 10μM (Figure 2E). At 0.5μM and 10μM CCh,
the KCNQ current remaining was 81 ± 7% (n = 5), and 54 ± 6%
(n = 5), respectively (Figure 2F). These data indicate that KCNQ
channels are weakly inhibited by muscarinic agonist, and may
participate in control of membrane potential.
KCNQ CHANNEL OPENERS OPPOSE MUSCARINIC-INDUCED
DEPOLARIZATION OF ASM CELLS
Since KCNQ channels are known to control membrane potentials
in both nerve and other smooth muscle types, we investigated
if they similarly control ASM membrane voltage, using flupir-
tine and XE991 application while voltages were being measured
under perforated-patch, whole-cell current clamp of single tra-
cheal cells. In contrast to the voltage-clamp studies above, these
measurements were made in the absence of BK channel block-
ers to evaluate the physiological contribution of KCNQ channels
to control of membrane voltage. As such, voltage oscillations
that are reflective of BK channel-mediated spontaneous hyper-
polarizations (Zhuge et al., 2010) become apparent in the voltage
tracings. A representative experiment is shown in Figure 3A, in
which flupirtine (10μM) induced a significant hyperpolariza-
tion, whereas XE991 (10μM) depolarized the cell. Such data are
summarized in Figure 3E, in which flupirtine hyperpolarized the
cells by 5.7 ± 0.8mV (n = 6) and XE991 depolarized them by
4.7 ± 1.1mV, relative to control (n = 6). The significant effect
of flupirtine and XE991 is consistent with the significant KCNQ
channel conductance (Figure 2C) starting at the approx. −40mV
resting voltage observed in these cells (Figure 3A, right panel).
We next tested whether the KCNQ channels also affect mem-
brane voltage under mAChR stimulation. Given that KCNQ
channel currents are largely active in the presence of CCh at
its EC50 value for inducing contractions (∼80%, Figure 2F), we
were surprised to see that XE991 had no significant effect on
membrane voltage in the presence of 0.5μM CCh (Figure 3B),
although flupirtine still induced a significant hyperpolarization.
Such data are summarized in Figure 3E, in which flupirtine
hyperpolarized the cells by 3.8 ± 1.0mV (n = 5) whereas there
was no significant depolarization induced by XE991 in the pres-
ence of CCh. This suggests that although KCNQ channels control
resting voltage, they may not be necessary for membrane repolar-
ization during muscarinic-evoked contractions.
Parasympathetic release of ACh, andM2 andM3 mAChR stim-
ulation is the predominant mechanism mediating contraction of
airway (Struckmann et al., 2003). Activation of Gq-coupled M3
mAChRs and Gi-coupled M2 mAChRs both can evoke tracheal
contractions in the absence of the other (Stengel et al., 2002;
Semenov et al., 2011). We hypothesized that the lack of effect of
KCNQ channels on membrane voltage during muscarinic stim-
ulation could either be due to Gq-coupled muscarinic inhibition
of the channels, or alternatively, due to functional redundancies
with other K+ channels, such as BK calcium-activated K+ chan-
nels that regulate membrane voltage during muscarinic-evoked
contraction. To address the former, we included the M3 recep-
tor antagonist J104129 Fumarate (5 nM) (Mitsuya et al., 1999)
to measure effects of XE991 on membrane voltage independent
of M3 receptor activation. In the presence of the M3 antago-
nist, we again saw no significant effect of XE991 on membrane
voltage (Figure 3C, summarized in Figure 3E). To address the lat-
ter possibility, we repeated these experiments and included the
BK channel blocker paxilline (1μM). Under these conditions,
XE991 indeed significantly depolarized membrane voltage during
muscarinic stimulation (Figure 3D, summarized in 3E). On aver-
age, the XE991 depolarization (2.8 ± 0.7, Figures 3D,E) with BK
channel block was somewhat smaller than XE991 depolarization
in the absence of muscarinic activation (4.7 ± 1.1, Figures 3A,E).
However, we did not see a significant difference between the
two (P = 0.21, unpaired t-test). These results are consistent with
KCNQ channels being required for control of membrane volt-
age at rest, but having a redundant role with BK channels during
muscarinic signaling. On the other hand, the KCNQ agonist,
flupirtine, hyperpolarized the membrane voltage under all cir-
cumstances (Figure 3E) indicating that such openers can recruit
KCNQ channels to oppose muscarinic-evoked depolarization.
KCNQ CHANNEL BLOCKERS DO NOT INCREASE
MUSCARINIC-INDUCED CONTRACTION OF TRACHEAL RINGS, BUT
KCNQ OPENERS REDUCE IT
Previously, others have shown that KCNQ channel antagonists
constrict airways in human lung slices (Brueggemann et al.,
2012). Here we investigated the effects of KCNQ channels on
rodent airway contractility using isometric tensionmeasurements
of tracheal rings. As above, we used flupirtine and XE991 to probe
the role of KCNQ channels in CCh-induced contractility. Using
0.5μM CCh to elicit tracheal ring contractions, we observed a
moderate relaxation (∼20%) with flupirtine (Figure 4). Similar
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FIGURE 3 | KCNQ channels affect airway smooth muscle membrane
potentials. Membrane potentials were measured in perforated patch,
current-clamp mode. For (A–D), left panels show representative
experiments, right panels show average voltage. Statistical significant
differences (paired t-test) from control (A) or carbachol (0.5μM) treatment
(B–D), is indicated with asterisks. (A) Effects of KCNQ agonist flupirtine and
antagonist XE991 on membrane potentials at rest (absence of carbachol).
Average control −39.2 ± 1.7, flupirtine −45.1 ± 1.8, XE991 −35 ± 1.7.
N = 6. (B) Effects of KCNQ agonist flupirtine and antagonist XE991 on
membrane potentials with a cell pre-treated with carbachol. Average control
−39.5 ± 2.4, carbachol −30.4 ± 3.4, flupertine −33.6 ± 3.9, XE991
−30.1 ± 3.7. N = 5. (C) Effects of flupirtine and XE991 on membrane
potential in cells pre-treated with M3 receptor antagonist J104129 fumarate
and carbachol. Average control −42 ± 1.9, carbachol −37.8 ± 2.1, flupirtine
−41 ± 1.9, XE991 −36.6 ± 2.2. N = 4. (D) Effects of flupirtine and XE991
on membrane potential with a cell pre-treated with M3 receptor antagonist
J104129 fumarate (5 nM), BK channel antagonist (1μM paxilline) and
muscarinic agent (0.5μM carbachol). Average control −40.6 ± 2.3, paxilline
−32 ± 2.1, carbachol −28.9 ± 2.0, flupirtine −33.1 ± 1.8, XE991
−26.5 ± 2.4. N = 5. (E) Average change in voltage (V) due to flupertine
(white) or XE991 treatment (gray) from control (A) or carbachol treatment
(B–D) measured in (A–D). Changes in voltage for flupirtine and XE991,
respectively, are as follows; control: −5.7 ± 0.8, +4.7 ± 1.1; carbachol:
−3.8 ± 1, +0.4 ± 0.3, J104129 fumarate and carbachol: −5.1 ± 1.1,
+0.5 ± 0.3; J104129 fumarate, J104129 fumarate, paxilline, and carbachol:
−5.6 ± 1.2, +2.8 ± 0.7. ∗p < 0.05; ∗∗p < 0.001; ∗∗∗p < 0.0001. Significant
differences, indicated with asterisk, were determined using a one-sample
t-test. NS indicates no significant difference.
to the studies above on voltage (Figure 3), XE991 had no effect on
contractility during muscarinic activation (Figures 4A,B). Very
similar effects were also seen in mouse trachea (Figure 4B). For
rat trachea, the percent of high-K+ contraction was 130 ± 4%
(n = 12), 112 ± 4% (n = 12, p < 0.005), and 135± 7% (n = 12)
in control, flupertine and XE991, respectively. For mouse tra-
chea, the percent of high-K+ contraction was 131 ± 3% (n = 3),
108 ± 2% (n = 3, p < 0.001), and 133 ± 4% (n = 3) in control,
flupertine and XE991, respectively. The significant effect of the
KCNQ-channel opener for both rat and mouse trachea suggests
that at potentials where both KCNQ K+ and L-type voltage-gated
calcium channels (VGCCs) channels are activated, M-channel
openers can moderate ASM contraction. As a further test, when
we used a low (1mM) K+ external solution to hyperpolarize
trachea membrane voltage negative to the voltage threshold for
activation of L-type Ca2+ channels, there was no effect of flupir-
tine on the CCh-induced contraction (Figure 4C). In control, the
percent of high-K+ contractions was 69 ± 3% (n = 3), and in
flupirtine, it was 71 ± 4% (n = 3). This is consistent with a spe-
cific effect of flupirtine onmembrane voltage via KCNQ channels.
In contrast to the effect of flupirtine, XE991 had no effect on CCh-
induced contractions (Figure 4B), suggesting that whereas KCNQ
channel blockade does not increase contractions, augmenting
KCNQ currents moderates CCh-induced ASM contractions.
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FIGURE 4 | KCNQ channel opener but not antagonist affect airway
smooth muscle contractility. (A) Representative rat trachea contraction
evoked by 0.5μM carbachol alone (control) or in the presence of 10μM
flupirtine. (B) Summary tension values for rat and mouse tracheas treated
with 0.5μM carbachol and 10μM flupirtine or 1μM XE991. (C) Effect of
flupirtine on 0.5μM carbachol contraction is occluded by a hyperpolarizing,
low K+ bath solution. Contractions were conducted in mouse tissues.
∗p < 0.05; ∗∗p < 0.001, evaluated by unpaired, two-tailed t-test.
The lack of effect of XE991 on CCh-induced contraction may
be explained by a robust BK channel current that is sufficient
to limit depolarization. To test this hypothesis, we compared the
effect of XE991 on contractility of WT mice to mice with a genet-
ically ablated BK channel β1 subunit. β1 KO mice have increased
tracheal constrictions due to reduced activation of BK channels
(Semenov et al., 2006, 2011). Tracheal contraction was evaluated
over a range of CCh concentrations, in the presence or absence
of XE991. Consistent with the data in Figure 4 we found that
XE991 did not affect CCh-induced trachea contractions in WT
mice over the entire range of [CCh] (Figure 5A). However, when
BK channel function was perturbed by KO of the BK β1 subunit,
we indeed found that KCNQ channel blockade caused increased
CCh-evoked contractions that was most pronounced at modest
CCh concentrations (Figure 5B). To provide a more physiolog-
ical paradigm of muscarinic stimulation, we used electrical field
stimulation of our intact nerve/trachea preparation, at both mod-
erate and high stimulation rates that should corresponding to
modest, or high, [CCh] in Figure 5A. Contractions, measured at
stimulation rates of 3Hz or 20Hz were compared in the pres-
ence or absence of XE991. However, as in Figure 5A, blockade
of KCNQ channels did not alter the responses to either high or
low stimulation, or the ratio between them (Figure 5C). Such
data are summarized in Figure 5D. In control, the percent of
high-K+ contraction was 20 ± 2.4% and 43.0 ± 6.6% (n = 5) at
3Hz and 20Hz, respectively, and in the presence of XE991, it was
22.7 ± 2.9% and 42.5 ± 3.9% (n = 5), respectively.
PERTURBATION OF BK CHANNEL FUNCTION ALLOWS THE KCNQ
CURRENT TO ASSUME A LARGER ROLE IN OPPOSING ASM
CONTRACTIONS
The lack of effect of KCNQ blockade on trachea contractil-
ity (Figure 4) is consistent with its lack of effect on membrane
potential during muscarinic signaling (Figure 3). We investi-
gated this further using the M3 receptor antagonist J104129
fumarate (5 nM) and BK channel β1 KO mice to understand
how muscarinic Gq-coupled signaling or redundancies with BK
channels, respectively affect the role of KCNQ channels in ASM.
We performed these tests at 0.5μM CCh, a concentration that
produces half-maximal contractions, and at which there was no
effect of XE991 both in WT and KO trachea (Figures 5A,B).
J104129 fumarate itself reduced the average contractile response
to 0.5μM CCh by about 30 and 45% in WT and KO trachea,
respectively, consistent with M3 receptor-mediated Ca2+ release
of intracellular stores playing a large role in muscarinic-induced
contractions of ASM (Figure 5E). Interestingly, whereas XE991
had no effect on J104129 fumarate-treated muscarinic contrac-
tion of trachea from wild type mice, the KCNQ channel blocker
potentiated the response to CCh by some 1.6-fold in trachea of
β1 KO mice (Figure 5E). For WT trachea, the percent of high-
K+ contraction was 84 ± 4.7% and 87 ± 4.3% (n = 8) in the
presence or absence of XE991, respectively, whereas in KO tra-
chea, they were 94 ± 10.8% and 149 ± 4.9% (n = 7, p < 0.001),
respectively. These results suggest that when BK channels are
fully active, KCNQ channels may be functionally redundant in
limiting contractions from membrane depolarization. However,
when BK channel function is perturbed, as when the β1 subunit
is lacking, KCNQ channels are essential in limiting depolariza-
tions, which likely increase airway contraction via influx of Ca2+
through L-type VGCCs. These data further indicate that the lack
of significant effect of XE991 at higher CCh concentrations in
the KO trachea (Figure 5B) is probably due to KCNQ channels
already being inhibited by stimulation of Gq/11-coupled M3 mus-
carinic receptors (as in Figure 2F). Thus, when that PLC-linked
mechanism of KCNQ current depression is occluded by recep-
tor blockade, a very significant effect of blocking KCNQ channels
is revealed. In the discussion, we elaborate on the significance of
these findings, in the context of asthmatic syndromes associated
with altered expression of BK β1 subunit expression.
KCNQ CHANNEL OPENERS RETARD MUSCARINIC-INDUCED AIRWAY
CONSTRICTION IN LIVE MICE
We wished to further investigate the in vivo role of KCNQ chan-
nels in pulmonary function. We used non-invasive whole animal
plethysmography. This technique reports measurements of air-
way function during normal, passive breathing. Plethysmography
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FIGURE 5 | Effect of KCNQ antagonist is apparent when BK K+ channels
function is perturbed and M3 receptor activation is blocked. Effect of
KCNQ antagonist XE991 assayed in (A) wild type mice and (B). BK channel
β1 knockout mice. (C) Contractions evoked by electric field stimulation in wild
type mice. (D) Summary of (C). (E) Summary of contractions evoked by
0.5μM carbachol and M3 muscarinic acetylcholine receptor antagonist
J104129 fumarate (5 nM) alone, or with KCNQ antagonist XE991 (1μM).
∗p < 0.05; ∗∗p < 0.001, evaluated by unpaired, two-tailed t-test.
does not provide a direct measure of airway resistance, but rather
provides an estimate of an enhanced pause (PenH) in breath-
ing mechanics that is correlated to increases of airway resistance
(Lomask, 2006). Because airway resistance has a cumulative effect
upon repeated muscarinic stimulation, we tested the effects of
the clinically approved KCNQ agonist retigabine (RTG, 200μM)
when it was combined with a second challenge of methacholine
(50mg/ml). PenH was monitored for 10min following the sec-
ond challenge with methacholine, either alone or when combined
with RTG. Both WT and KO mice displayed a substantially
increased PenH value upon the second challenge of methacholine,
compared to the first (compare McH1 vs. McH1 + McH2 in
Figure 6A, 10min average response). We examined the PenH
response on a temporal basis and calculated the individual 1min
average time-points following the second McH2 or McH2/RTG
challenges, as plotted in Figures 6B,C. The data show RTG to sig-
nificantly reduce the PenH value in both wild type and β1 KO
mice during the early 2–6min of the second challenge. The differ-
ence is most significant at early timepoints, with decreased effect
of RTG during the later 6–10min time window. Thus, the effect
of KCNQ activation is most significant in the initial 6min after
muscarinic stimulation, whereas its role is less during sustained
contractions. These results are consistent with the in vitro tracheal
studies showing that KCNQ channel activation reduces muscle
contraction during muscarinic stimulation (Figure 4).
DISCUSSION
A major observation of this study is that KCNQ channels con-
trol resting membrane potential of ASM, which is consistent with
their activation at relatively negative (> −40mV) membrane
potentials. However, muscarinic activation eliminated the effect
of KCNQ blockade on membrane potential. While KCNQ ago-
nist flupirtine relaxed muscarinic-evoked contractions, KCNQ
FIGURE 6 | Retigabine transiently reduces bronchoconstriction by
methacholine. Penh was measured in conscious wild type (WT) and BK-β1
knockout (BK-β1 KO) mice. Measurements were before and after
introduction of nebulized methacholine (McH, 50mg/ml) into the
plethysmography chambers. After an initial challenge of McH (McH1),
followed by a 20min rest, a second McH challenge (McH2) was given,
either alone or together with nebulized retigabine (RTG, 200 uM) and Penh
was measured for 10min. The Penh baseline values were subtracted from
the data. (A) The second dose of methacholine significantly increases
airway resistance. Penh during the first McH challenge was averaged over
10min and compared with the 10min Penh average of the second
challenge of McH (McH2). (B,C) Penh is plotted for each minute average of
the second McH challenge, either alone or together with RTG, for either
WT (B) or BK-β1 KO (C) mice. #p < 0.05; ##p < 0.001, evaluated by
unpaired t-test corrected for multiple comparisons by Holm Sidak method.
∗p < 0.05; ∗∗p < 0.001, evaluated by paired, two-tailed t-tests.
blockade did not enhance it. This suggests that, although KCNQ
channels can be pharmacologically recruited to relax airway, they
do not contribute to relaxation during muscarinic-evoked con-
tractions. In part, one might expect that the mechanism would
be due to inhibition by signaling downstream of muscarinic
receptor activation and that the muscarinic-evoked depolariza-
tion of ASM could be due to muscarinic inhibition of KCNQ
channels. However, voltage clamp recordings indicate muscarinic
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agonist only weakly inhibits KCNQ channels (∼19% inhibition at
0.5μM CCh, 46% at 10μM CCh (Figure 2F), approximate EC50
and maximum concentrations for contraction, respectively). This
contrasts with sympathetic neurons that show 80–90% KCNQ
current inhibition at 10μM muscarinic agonist (Beech et al.,
1991; Bernheim et al., 1992). Further, blocking M3 receptors
alone did not uncover control by KCNQ channels (XE991)
on voltage or contractions during muscarinic signaling. Rather,
the data indicate that functional redundancy with BK channels
reduces the contribution of KCNQ channels during ACh-evoked
contractions. At low muscarinic agonist concentrations, the BK
β1 KO was sufficient to reveal effects of XE991. At higher mus-
carinic agonist concentrations the combination of β1 KO and
M3 receptor blockade revealed a significant effect of KCNQ
channels on membrane voltage (Figures 3D,E) and contraction
(Figure 5E). Thus, we conclude that KCNQ channels have func-
tional redundancy with BK channels, especially when combined
with strong Gq/11-mediated muscarinic inhibition, which mini-
mizes their role during muscarinic-evoked contractions. Further,
we can conclude that KCNQ channel inhibition is unlikely to
underlie muscarinic depolarization of ASM. Indeed, the roles
of KCNQ and BK channels may be considered complementary.
Low-voltage threshold KCNQ channels likely control membrane
potential at resting voltages when intracellular calcium is low.
During muscarinic signaling, BK channels assume a greater role
due to the depolarized membrane potential and elevated calcium
that support BK channel activation.
The in vitro constriction study supports a supplementary role
for KCNQ channels in control of airway contractility when BK
K+ channel activation is perturbed. This is further supported by
in vivo experiments showing that RTG reduces the PenH index.
Although the whole animal plethysmography may also reflect
changes in breathing independent of airway resistance (Glaab
et al., 2007), the results are consistent with the constriction exper-
iments. Thus, retigabine, a drug already approved for human
treatment in epilepsy, might be an effective bronchodilator par-
ticularly under pathological conditions where BK channel expres-
sion or function is perturbed. Indeed, human polymorphisms
for the BK channel β1 subunit have been identified that perturb
BK/β1 function and correlate highly with increased asthma sever-
ity (Seibold et al., 2008) and retigabine in these individuals may
serve as a tailored therapy. As well, there are a number of stud-
ies showing downregulation of BK channel β1 in diseases such
as hypertension (Nieves-Cintron et al., 2008), aging (Nishimaru
et al., 2004), diabetes (McGahon et al., 2007a,b; Zhang et al., 2010;
Lu et al., 2012), and bladder overactivity (Chang et al., 2010). If
BK channels are also inhibited during diseases of the airway such
as asthma, then KCNQ channels may become particularly more
relevant in control of airway contractility.
This study in rodents support past studies showing KCNQ
channel expression in ASM of guinea pig and human tissues
(Brueggemann et al., 2012). However, these studies contrast with
previous studies insofar as KCNQ channel effects on airway
contractility. Previous studies assayed diameter changes of bron-
chioles in human lung slices. In those studies, blockade of KCNQ
channels profoundly enhanced histamine-induced constriction
(Brueggemann et al., 2012). In these studies, we measured iso-
metric contractions using tracheal rings and saw no significant
effect of KCNQ blocker on membrane voltage or contractility
during application of muscarinic agonists, the main physiological
stimulus for ASM contraction in the living animal. We specu-
late that the discrepancy may be due to differences in the relative
contribution of KCNQ channels in rodent and human lung.
Rodents may have a greater contribution of BK or other K+ chan-
nel in lower ASM, whereas human lung may be more reliant
on KCNQ channels. Further studies should elucidate the rela-
tive contribution of these two channel types in lower airway of
rodents.
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